Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: Systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 2017;74(7):675–84. https://www.ncbi.nlm.nih.gov/pubmed/28514486
Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016;50(5):410–72. https://www.ncbi.nlm.nih.gov/pubmed/27106681
Siskind DJ, Lee M, Ravindran A, Zhang Q, Ma E, Motamarri B, et al. Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. Aust N Z J Psychiatry 2018;52(8):751–67. https://www.ncbi.nlm.nih.gov/pubmed/29732913
Wagner E, Kane JM, Correll CU, Howes O, Siskind D, Honer WG, et al. Clozapine combination and augmentation strategies in patients with schizophrenia -recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. Schizophr Bull 2020;46(6):1459–70. https://www.ncbi.nlm.nih.gov/pubmed/32421188
Wagner E, Lohrs L, Siskind D, Honer WG, Falkai P, Hasan A. Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance. J Psychopharmacol 2019;33(4):423–35. https://www.ncbi.nlm.nih.gov/pubmed/30696332